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Summary
Objective: The present study was aimed at determining the serodiagnostic potential of 38-kDa
(Rv0934, Mycobacterium tuberculosis complex-specific antigen) and CFP-10 (Rv3874, RD1 anti-
gen) antigens among HIV-positive and HIV-negative patients with pulmonary TB.
Methods: The diagnostic potential of native 38-kDa (n38-kDa) and recombinant CFP-10 (rCFP-10)
antigens was ascertained in terms of sensitivity and specificity using an indirect ELISA. The study
included 508 HIV-seronegative TB patients (TB), 54 HIV-seropositive TB patients (HIV—TB), 30 HIV-
positive patients without TB (HIV), and 256 controls.
Results: In HIV—TB, the sensitivities for individual antigens ranged from 14.8% to 31.5% and the
specificity was >98% for IgG. When IgA results were added to IgG, the sensitivity increased to
25.9% for 38-kDa and 57.4% for CFP-10; specificity changed to 97.5% for 38-kDa and 98.1% for CFP-
10. The combined results of both the antigens gave 59.3% sensitivity and 95.6% specificity. In TB,
the sensitivity was 82.8% when the antigen results were combined. None of the HIV-infected
controls showed positivity for IgG to either of the two antigens.
Conclusion: Use of CFP-10 enhances the sensitivity of 38-kDa, and therefore the 38-kDa and CFP-
10 antigen combination can be a diagnostic marker in HIV—TB.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
The increasing incidence of tuberculosis (TB) on account of
its association with AIDS is unquestionably a cause of global* Corresponding author. Tel.: +91 (044) 2836 9626;
fax: +91 (044) 2836 2528.
E-mail address: alameluraja@yahoo.com (A. Raja).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.09.022concern. TB is the leading cause of death among persons with
AIDS, killing one of every three people who die of AIDS.1
TB and HIV infections are both intracellular and known to
have profound influence on each other’s progression. More-
over, the emergence of multidrug-resistant strains is also a
significant threat to TB control.2 In spite of the availability of
an adequate treatment regimen for TB, attempts to restrict
and eradicate the disease have failed. Delayed diagnosis ofPublished by Elsevier Ltd. All rights reserved.
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after presentation are associated with 45—85% of deaths in
HIV-infected patients.3 Therefore accurate and early diag-
nosis of TB in HIV-infected patients will aid in the better
management of this disease and hence improve the survival
rate of these patients.
The clinical features of TB in HIV-infected persons are often
non-specific, hence diagnosis can be difficult. The conven-
tional acid-fast staining method accounts for only 50% case
detection in HIV—TB patients.4 By the time the culture results
are available,Mycobacterium tuberculosiswould have caused
clinical deterioration. PCR-based methods are expensive.
Decreased tuberculin reactivity, atypical radiographic fea-
tures, and confusion with other HIV-related infections hinder
thediagnosis ofTB inHIV-infectedpatients.5 Therefore,better
diagnostic methods are needed for HIV—TB.
Alternative methods for the detection of M. tuberculosis
based on serologic response to mycobacterial antigens have
been reported. There is promise in serodiagnostic tests like
ELISA because of their ease of performance, cost-effective-
ness, and high specificity if species-specific antigens are used.
The importance of purified, well-characterized antigens in
ELISA,6—9 as opposed to crudeextracts,10,11 iswell recognized.
The major drawback in such assays is the extensive person-to-
person variation in antibody response, leading to poor sensi-
tivity when a single antigen is used. In this scenario, the
prospective approach would be to use more than one antigen
for the diagnosis of TB in HIV-infected patients.
The RD1 gene product, culture filtrate protein-10 (CFP-10,
Rv3874) is an early-secreted, M. tuberculosis complex-spe-
cific antigen and hence a suitable candidate to be used in
diagnosis. Since the RD1 region is absent in Mycobacterium
bovis bacille Calmette—Guerin (BCG), prior vaccination with
BCG will not give false-positive results.
The present study was undertaken in order to evaluate the
diagnostic value of CFP-10 in HIV—TB cases. The ability of
CFP-10 to enhance the sensitivity when combined with
another well-characterized M. tuberculosis complex-specific
antigen, 38-kDa (Rv0934), was investigated. Moreover, 38-
kDa and CFP-10 are known to diagnose advanced cavitary TB
and non-cavitary TB, respectively. Hence, their combination
may be a potential diagnostic candidate.
Materials and methods
Study subjects
The study was approved by the institutional ethics commit-
tee, and informed consent was obtained from the study
subjects. Patients were recruited from the Tuberculosis
Research Centre, Chetput, Chennai, India between 2001
and 2005. Eight hundred and forty-eight subjects were
included, of whom 508 (59.9%) were HIV-negative pulmonary
TB patients, 54 (6.4%) were HIV-infected TB patients, and 286
(33.7%) were controls.
Blood was collected from the patients prior to starting
treatment. The groups included in the present study are
listed below.
HIV-seronegative TB patients (TB group; N = 508)
The clinical criteria for diagnosis of HIV-seronegative TB
patients included the presence of two or more symptoms,namely cough formore than 2 weeks, fever, weight loss, night
sweats, anorexia, and hemoptysis.
Of the 508 HIV-negative pulmonary TB patients, 262 were
smear- and culture-positive (S+C+), of whom 197 were male
and 65 female, with ages ranging from 20 to 87 years, median
42 years. Of the remaining 246 smear-negative cases, 60
(24.4%) were culture-positive (SC+), with a male:female
ratio of 3:1 and an age range of 20—80 years, median 44
years. The remaining 186 patients were smear- and culture-
negative (SC), clinically and radiologically diagnosed
cases. This group consisted of 139 males and 47 females,
with ages ranging from 20 to 80 years, median 40 years. The
X-rays were read by two independent readers (and by one
more reader in the case of a disagreement between the two).
These patients were placed on a regimen of broad-spectrum
antibiotics for a period of 3 weeks and the X-rays were
repeated. The X-ray abnormality persisted and the patients
were placed on anti-tuberculous therapy (Category III
Revised National Tuberculosis Control Programme (RNTCP)
regimen); they responded to the therapy and had a good
clinical outcome, and hence were considered as pulmonary
TB patients.
Examination of smears and cultures was done according to
the methods established at our center.12 Two spot and one
overnight sputum specimens were collected from each
patient. Staining of acid-fast bacilli (AFB) with auramine—
phenol was done for smears and they were examined under a
fluorescence microscope. For culture, sputum was concen-
trated and inoculated onto Lowenstein—Jensen (LJ) medium
and incubated for up to 8 weeks at 37 8C in a non-CO2
atmosphere.
All patients were HIV-seronegative as tested by two
enzyme immunoassays (EIA; Comb Aids-RS, Span Diagnostics,
India and HIV TRI-DOT, J. Mitra & Co, India) in serum. There
were no co-morbid conditions along with the TB.
HIV-seropositive pulmonary TB patients (HIV—TB
group; N = 54)
There were 41 males and 13 females in this group, and their
age ranged from 20 to 67 years, with a median of 35 years.
The HIV status was confirmed by two rapid tests (EIA). When a
serum was positive in both tests, it was considered HIV-
positive. If a serum was positive for only one EIA (which
was rare), Western blot was done as a confirmatory test.
Pulmonary TB was bacteriologically confirmed by smear
and culture positivity (S+C+) in 29 of the patients. Of the
remaining 25 smear-negative patients, 14 were negative for
smear, but positive for culture (SC+) and 11 were negative
for both smear and culture (SC). These 11 were initially
classified as HIV—TB based on clinical suspicion without
bacteriological evidence; they recovered on anti-tubercu-
lous therapy, thus justifying their classification. Their CD4
counts ranged from 12 to 1052  103 cells/mm3 (mean CD4
265.24, SD 227.07; median CD4 167).
HIV-seropositive patients without TB (HIV group;
N = 30)
This group consisted of 19 males and 11 females, with age
ranging from 20 to 52 years, median 32 years.
HIV status was confirmed by two rapid tests as previously
described. These patients ranged in their clinical status from
asymptomatic cases to those with opportunistic infections
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candidiasis, skin diseases due to fungal infections, diarrhea
due to bacterial and viral causes, meningitis other than TB,
and carcinomas of the ovary and gastrointestinal tract. Their
CD4 counts ranged from 49 to 836  103 cells/mm3 (mean
CD4 307.53, SD 169.01; median CD4 286). TB was ruled out by
X-ray, smear, and culture.
Non-TB controls (N = 96)
This category included subjects with symptoms of TB (cough,
fever, loss of appetite, etc., but normal X-rays) and indivi-
duals with other lung diseases (bronchial asthma, lung car-
cinoma, pneumonia, etc., with X-ray shadows). The
male:female ratio was 2.7:1. Their ages ranged from 20 to
80 years, with a median of 44 years. TB was ruled out in this
group by sputum smear and culture. All 96 patients were HIV-
seronegative as evident by two EIAs.
Among patients who presented with other lung diseases,
24 had pneumonia: Streptococcus pneumoniae (n = 10), Kleb-
siella spp (n = 7), Mycoplasma pneumoniae (n = 4), and Chla-
mydia spp (n = 3); 52 patients had other lung diseases,
including bronchial asthma (n = 25), chronic obstructive pul-
monary disease (n = 13), bronchiectasis (n = 7), lung cancer
(n = 4), and other miscellaneous conditions (n = 3). The
remaining 20 subjects had TB symptoms without any lung
disease.
Normal healthy subjects (NHS group; N = 160)
These subjects were apparently normal without any clin-
ical symptoms. They were laboratory and blood bank
volunteers in whom HIV and TB infections were ruled out
by blood tests and chest X-ray, respectively. The subjects
of this category were negative for smear and culture. One
hundred and ten males and 50 females were included.
Their age ranged from 20 to 60 years, with a median of
40 years.
Latent TB, BCG status, and the tuberculin skin
test
The presence of antibodies due to sub-clinical latent TB
infection (LTBI) and prior BCG vaccination has often been
stressed as a complicating factor for serology of TB in the
literature. Since childhood BCG vaccination is a policy in
India, the majority of the patients may have been BCG
vaccinated. Data on BCG vaccination status were not col-
lected in this study. However, all study subjects were adults
(>20 years), and previous studies from our laboratory have
established that remote BCG vaccination does not influence
the antibody response over and above that of background
levels of antibodies found in endemic populations.13
The tuberculin skin test (TST) was not carried out in the
study subjects. It is neither specific nor sensitive in this TB
endemic area, especially in adults. It has been observed that
>70% of females and >80% of males turn positive for purified
protein derivative (PPD-S) by 25 years of age due to exposure
to M. tuberculosis, as well as other environmental mycobac-
teria. Thus TST positivity in our population does not mean
infection with M. tuberculosis alone, as in the case of non-
endemic populations.14,15
Blood samples were collected, and serum was separated
and stored sterile at 70 8C until use.Antigens
Isolation and purification of native 38-kDa (n38-kDa)
The 38-kDa antigen was purified by two-dimensional pre-
parative electrophoresis (employing Rotofor fluid phase iso-
electric focusing in the first dimension and Prepcell
electrophoresis in the second dimension), from M. tubercu-
losis H37Rv culture filtrate (CFA).16 Details of the method,
data on purity (immunoblotting with a polyclonal antiserum
against M. tuberculosis H37Rv culture filtrate), and identity
of the antigen to the already reported 38-kDa (Antigen 5,
Rv0934; immunoblotting with reference monoclonal anti-
body MAb IT-23 from the World Health Organization Bank)
have been reported previously.16
Isolation and purification of recombinant CFP-10
(rCFP-10)
MTSA-10(M.tuberculosis-specificantigen-10/CFP-10)waspre-
pared in the laboratory of Dr Pawan Sharma, ICGEB,NewDelhi,
India. In brief, the open reading frame Rv3874 encoding MTSA-
10 ofM. tuberculosiswas amplified by PCR from genomic DNA.
The PCR product was then directly cloned in an intermediate
vector (pGEM-T-Easy). After nucleotide sequence validation,
the full-length genewas sub-cloned in the bacterial expression
vector pQE-31 for expression as a polyhistidine-tagged recom-
binantMTSA-10protein inEscherichia coli. RecombinantMTSA-
10 was purified by nickel nitrilotriacetic acid (Ni—NTA) metal
affinity chromatography. Details of themethod, data on purity
(immunoblotting with a mouse antipolyhistidine monoclonal
antibody), and concentration of lipopolysaccharide inMTSA-10
preparation have been reported previously.17
ELISA
ELISA was carried out to estimate the IgG and IgA antibody
levels in sera against the n38-kDa and rCFP-10 antigens as
described previously.16 The 96-well polystyrene plates (Flat-
bottom, Nunc-ImmunoMaxisorp polystyrene plates, Nunc A/S,
Denmark) were coated with an antigen concentration of 1 mg/
ml for n38-kDa and 2 mg/ml for rCFP-10, and incubated over-
night at4 8C.Eachantigenwascoated individually. Plateswere
blocked with 1% casein and 10% normal goat serum for 1 h at
37 8C. Sera were used at 1:2000 dilution for IgG measurement
and 1:500 for IgA, as fixed by prior standardizing experiments,
and then incubated for 1 h at 37 8C. Plates were washed in
between every step (3—5) using phosphate-buffered saline
containing 0.1% Tween. Goat antihuman IgG/IgA peroxidase
conjugates (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) were used at 1:10 000 dilution for IgG and
1:5000 for IgA in blocking solution. Plates were washed (7)
after incubation for 1 h at 37 8C. Ortho-phenylene diamine
(OPD; Sigma Chemical Co., St Louis, USA) was used as the
substrate, and the color development was arrested with 8N
H2SO4. Finally the plates were read at 490 nm with 650 nm as
the correction wavelength using a Spectromax ELISA reader
(Molecular Devices, USA).
Statistical design and analysis
The IgG and IgA cut-off value for each antigenwas ascertained
using receiver—operator characteristic (ROC) curve analysis
between normal healthy subjects and S+C+ TB patients. The
Table 1 Demographic profile of subjects recruited
Group n (%) Male (%) CD4 counts 103 cells/mm3 (median) Age range in years (median)
TB 508 (59.9) 381 (75) NA 20—87 (42)
S+C+ 262 (30.9) 197 (75.2) NA 20—87 (42)
SC+ 60 (7.1) 45 (75) NA 20—80 (44)
SC 186 (21.9) 139 (74.7) NA 20—80 (40)
HIV—TB 54 (6.4) 41 (75.9) 12—1052 (167) 20—67 (35)
S+C+ 29 (3.4) 21 (72.4) 25—1052 (154) 23—54 (37)
SC+ 14 (1.7) 12 (85.7) 36—969 (140) 21—67 (35)
SC 11 (1.3) 9 (81.8) 12—513 (202) 20—59 (33)
NHS 160 (18.9) 110 (68.8) NA 20—60 (40)
HIV 30 (3.5) 19 (63.3) 49—836 (286) 20—52 (32)
Non-TB controls 96 (11.3) 70 (72.9) NA 20—80 (44)
Total 848 (100) 621 (73.2) NA NA
TB, pulmonary tuberculosis patients; HIV—TB, HIV-seropositive tuberculosis patients; NHS, normal healthy subjects; HIV, HIV-infected
subjects; NA, not applicable; S+, smear-positive; S, smear-negative; C+, culture-positive; C, culture-negative.
Figure 1 IgG and IgA antibody levels for 38-kDa and CFP-10 antigen. NHS, normal healthy subjects; TB, pulmonary tuberculosis
patients; HIV, HIV-seropositive patients without TB; HIV—TB, HIV-seropositive tuberculosis patients; Non-TB, non-TB controls. Each dot
represents the optical density (OD) of a single serum specimen. The cut-off point for each antigen was determined using ROC curve
analysis. The lowest cut-off value with >95% specificity and good sensitivity was considered optimal and is represented by the
horizontal line (0.626 for 38-kDa IgG, 0.237 for CFP-10 IgG, 0.239 for 38-kDa IgA and 0.215 for CFP-10 IgA). Any sample exhibiting
absorbance above the cut-off value was classified as positive.
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was considered optimal. Any sample exhibiting absorbance
above the cut-off value was classified as positive. The indivi-
dual results for the isotypes IgGand IgAwerecombined.Pooled
TB sera were used as the high optical density positive control
andpooledNHS seraas the lowoptical densitypositivecontrol,
while phosphate-buffered saline containing 0.1% Tween was
used as the negative control, in each plate.
Predictive value
The predictive values for HIV-positive TB patients were
calculated18 based on the prevalence of TB in HIV patients
of Tamil Nadu.19,20
CD4 counts
The CD4 cell count was estimated in blood samples of HIV and
HIV—TB patients by flow cytometry. In brief, CD3+/CD4+ cells
from peripheral blood were labeled by the lysed whole blood
method, using the IMK lymphocyte kit (BD biosciences, CA,
USA). The percentage of CD4 cells among the total lympho-
cyteswas obtained from the FACSort (BDBiosciences, CA, USA)
using Cell Quest Software (BD Biosciences, CA, USA), and the
absolute CD4 countwas calculated bymultiplying this with the
total lymphocyte count. Pearson’s correlation coefficient was
used to measure the correlation between CD4 counts and
antibody levels. Significance of correlation was calculated
using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA).
Results
The demographic profile of the subjects enrolled in the study
is presented in Table 1. A scatter plot of IgG and IgA antibodyTable 3 Antibody positivity for CFP-10 antigen
Groups IgG
No. positive (%) a
TB (n = 508) 157 (30.9)
HIV—TB (n = 54) 17 (31.5)
NHS (n = 160) 1 (0.6)
HIV (n = 30) 0 (0)
Non-TB controls (n = 96) 2 (2.1)
TB, pulmonary tuberculosis patients; HIV—TB, HIV-seropositive tuberc
subjects.
a Number of positive sera (percentage of positivity); positivity, OD >
Table 2 Antibody positivity for 38-kDa antigen
Groups IgG No. positive (%)a
TB (n = 508) 286 (56.3)
HIV—TB (n = 54) 8 (14.8)
NHS (n = 160) 2 (1.2)
HIV (n = 30) 0 (0)
Non-TB controls (n = 96) 0 (0)
TB, pulmonary tuberculosis patients; HIV—TB, HIV-seropositive tuberc
subjects.
a Number of positive sera (percentage of positivity); positivity, OD >response to 38-kDa and CFP-10 antigens for the various
groups is shown in Figure 1. The cut-off value for each antigen
was determined using ROC curve and were identified as 0.626
for 38-kDa IgG, 0.239 for 38-kDa IgA, 0.237 for CFP-10 IgG,
and 0.215 for CFP-10 IgA.
Antibody levels to the 38-kDa protein
As shown in Table 2, the antibody response to 38-kDa anti-
genic stimulation in HIV—TB patients was 14.8% (95% CI 6.62—
27.12) for both IgG and IgA. ELISA positivity for both the
isotypes was less in HIV—TB patients than in pulmonary TB
patients. When individual results were scrutinized, it was
found that some sera negative for IgG were positive for IgA.
Combining the isotype results (IgG + IgA) gave 25.9% positivity
in HIV—TB patients.
In the NHS group, the specificity of the assay was 98.8% for
IgG, but dropped marginally to 97.5% upon combination of
IgG and IgA results. The non-TB control group gave >95%
specificity. In the HIV-positive TB-negative group, the speci-
ficity was 100% (95% CI 88.43—100.00) for IgG, and there was
one false-positive for IgA antibodies (Table 2).
Antibody levels to the CFP-10 protein
Antibody positivity to CFP-10 antigen in HIV—TB patients was
31.5% (95% CI 21.09—47.47) for IgG and 35.2% (95% CI 24.29—
51.26) for IgA isotypes (Table 3). ELISA positivity obtained
with each of the isotypes was similar in HIV—TB and TB
patients. On combining the isotype results, the sensitivity
in TB patients was 57.5% and in HIV—TB patients, 57.4%.
In the NHS group, the specificity of detection was 98.1%
with isotype combination. As for the 38-kDa antigen, the
specificity of CFP-10 in the non-TB control groupwas>95%. InIgA IgG + IgA
No. positive (%)a No. positive (%) a
203 (40.0) 292 (57.5)
19 (35.2) 31 (57.4)
2 (1.2) 3 (1.9)
5 (16.7) 5 (16.7)
1 (1.0) 3 (3.1)
ulosis patients; NHS, normal healthy subjects; HIV, HIV-infected
0.237 for IgG and >0.215 for IgA.
IgA No. positive (%)a IgG + IgA No. positive (%) a
153 (30.1) 348 (68.5)
8 (14.8) 14 (25.9)
2 (1.2) 4 (2.5)
1 (3.3) 1 (3.3)
4 (4.2) 4 (4.2)
ulosis patients; NHS, normal healthy subjects; HIV, HIV-infected
0.626 for IgG and >0.239 for IgA.
Table 4 Combination of antigen results (38-kDa + CFP-10)
Groups 38-kDa + CFP-10
IgG IgG + IgA
No. positive (%)a No. positive (%)a
TB (n = 508) 341 (67.1) 421 (82.9)
HIV—TB (n = 54) 22 (40.7) 32 (59.3)
NHS (n = 160) 3 (1.9) 7 (4.4)
HIV (n = 30) 0 (0) 6 (20)
Non-TB controls
(n = 96)
2 (2.1) 6 (6.3)
TB, pulmonary tuberculosis patients; HIV—TB, HIV-seropositive
tuberculosis patients; NHS, normal healthy subjects; HIV, HIV-
infected subjects.
a Number of positive sera (percentage of positive sera); posi-
tivity of 38-kDa, OD >0.626 for IgG and >0.239 for IgA; positivity
of CFP-10, OD >0.237 for IgG and >0.215 for IgA.
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(95% CI 88.43—100.00) for IgG, but five of 30 subjects were
positive for IgA antibodies (Table 3).
Combination of antigens
The results of 38-kDa and CFP-10 antigens were combined
and analyzed. In HIV—TB subjects, 38-kDa gave a positivity of
25.9% (Table 2), CFP-10 gave a positivity of 57.4% (Table 3),
and on combining the antigen results (38-kDa and CFP-10) the
sensitivity was 59.3% (Table 4). The specificity was marginally
reduced.
Antibody levels according to smear and culture
status
The overall results were split based on smear and culture
positivity and then analyzed. Of the 54 HIV—TB cases, 29
presented with smear- and culture-positive TB. Seven of
these (24.1%) were positive for 38-kDa and 18 (62.1%) were
positive for CFP-10. Of the 14 SC+ HIV—TB patients, four
(28.6%) were positive for 38-kDa and six (42.9%) for CFP-10.
Among 11 SC HIV—TB patients, three (27.3%) were posi-
tive for 38-kDa, while seven (63.6%) were positive for CFP-10.
When 38-kDa and CFP-10 results were combined and ana-
lyzed, 18 of 29 (62.1%) S+C+, six of 14 (42.9%) SC+, and eight
of 11 (72.7%) SC HIV—TB cases were diagnosed (Table 5).
In 508 HIV-negative TB patients, 182 of 262 (69.5%) S+C+
patients were positive for 38-kDa, 174 (66.4%) were positive
for CFP-10, and on combining the antigen results 234 (89.3%)
showed positivity. Of the 60 SC+ TB patients, 31 (51.7%)
were positive for 38-kDa, 39 (65%) for CFP-10, and 46 (76.7%)
were positive for the combined antigens. Among 186 SC
TB patients, 135 (72.6%) were positive for 38-kDa and 79
(42.5%) for CFP-10, which increased to 141 positives (75.8%)
on combining the antigen results (Table 6).Table 5 ELISA positivity among HIV—TB patients based on smear
Isotype S+C+ HIV—TB (n = 29)
No. positive (%)a
38-kDa
IgG 3 (10.3)
IgA 5 (17.2)
IgG + IgA 7 (24.1)
CFP-10
IgG 13 (44.8)
IgA 9 (31.0)
IgG + IgA 18 (62.1)
38-kDa + CFP-10
IgG 14 (48.3)
IgA 10 (34.5)
IgG + IgA 18 (62.1)
S+C+ HIV—TB, smear-positive and culture-positive HIV—TB patients; S
SC HIV—TB, smear-negative and culture-negative HIV—TB patients.
a Number of positive sera (percentage of positive sera); positivity of 38
>0.237 for IgG and >0.215 for IgA.Predictive values
A positive predictive value (PPV) of 0.78 for 38-kDa and 0.91
for CFP-10 was found in the HIV—TB group. Negative pre-
dictive values (NPV) were 0.80 for 38-kDa and 0.87 for CFP-
10. Combining the 38-kDa and CFP-10 antigens gave a PPV of
0.82 and an NPV of 0.87 (Table 7).
Antibody response of HIV—TB based on CD4
counts
The antibody levels and CD4 counts of HIV-infected TB
patients were analyzed for a correlation (Figure 2). CFP-10
antibody levels for IgG had a trend to increase with CD4 count
(r = 0.108) but the converse was true for the IgA isotype
(r = 0.167). The trend was not significant for either ofand culture status
SC+ HIV—TB (n = 14) SC HIV—TB (n = 11)
No. positive (%)a No. positive (%)a
2 (14.3) 3 (27.3)
3 (21.4) 0 (0)
4 (28.6) 3 (27.3)
4 (28.6) 0 (0)
3 (21.4) 7 (63.6)
6 (42.9) 7 (63.6)
5 (35.7) 3 (27.3)
4 (28.6) 7 (63.6)
6 (42.9) 8 (72.7)
C+ HIV—TB, smear-negative and culture-positive HIV—TB patients;
-kDa, OD>0.626 for IgG and>0.239 for IgA; positivity of CFP-10, OD
Table 7 Test characteristics for 38-kDa and CFP-10 antigens
Antigens IgG + IgA
Sensitivity % Specificity % PPV NPV
38-kDa 25.9 97.5 0.78 0.80
CFP-10 57.4 98.1 0.91 0.87
38-kDa + CFP-10 59.3 95.6 0.82 0.87
PPV, positive predictive value; NPV, negative predictive value.
Positivity of 38-kDa, OD >0.626 for IgG and >0.239 for IgA; positivity of CFP-10, OD >0.237 for IgG and >0.215 for IgA.
Table 6 ELISA positivity among TB patients based on smear and culture status
Isotype S+C+ TB (n = 262) SC+ TB (n = 60) SC TB (n = 186)
No. positive (%)a No. positive (%)a No. positive (%)a
38-kDa
IgG 148 (56.5) 19 (31.7) 119 (64.0)
IgA 70 (26.7) 16 (26.7) 67 (36.0)
IgG + IgA 182 (69.5) 31 (51.7) 135 (72.6)
CFP-10
IgG 125 (47.7) 11 (18.3) 21 (11.3)
IgA 97 (37.0) 34 (56.7) 72 (38.7)
IgG + IgA 174 (66.4) 39 (65) 79 (42.5)
38-kDa + CFP-10
IgG 200 (76.3) 21 (35) 120 (64.5)
IgA 123 (46.9) 36 (60) 86 (46.2)
IgG + IgA 234 (89.3) 46 (76.7) 141 (75.8)
S+C+ TB, smear-positive and culture-positive TB patients; SC+ TB, smear-negative and culture-positive TB patients; SC TB, smear-
negative and culture-negative TB patients.
a Number of positive sera (percentage of positive sera); positivity of 38-kDa, OD>0.626 for IgG and>0.239 for IgA; positivity of CFP-10, OD
>0.237 for IgG and >0.215 for IgA.
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38-kDa antigen (data not shown).
Discussion
The routine diagnostic methods for TB (smear and X-ray) are
not ideal for use in HIV—TB, due to lower sensitivity and non-
specificity. Serologic diagnostic tests using crude mycobac-
terial antigens such as culture filtrate antigen (CFA), PPD, and
antigen A60,10,11 as well as purified lipid antigens21—24 and
protein antigens,6—9 have been tried with varying results.
Among the available purified protein antigens, 38-kDa and its
epitopes have been well studied due to their specificity.
In the present study, using the n38-kDa antigen, a reduced
sensitivity of 14.8% (IgG, 95% CI 6.62—27.12) was obtained in
HIV—TB patients, compared with 56.3% (95% CI 52.46—61.24)
for TB patients. These results are comparable with those of
earlier reports.8,25 In our previous study,26 a sensitivity of 38%
was obtained (IgG) for HIV—TB patients, compared with 61%
for TB patients on using this antigen. In contrast, using r38-
kDa antigen, better sensitivities in HIV—TB (67—70%) have
been obtained compared to TB (40—58%).7,9
The response to 38-kDa is associated with advanced cavi-
tary TB.27 In the present study, the patients were not cate-
gorized as cavitary or non-cavitary, based on X-ray. However,there is evidence in the literature to show that HIV—TB is
associated with a reduced ability to develop cavitary
lesions.28 In order to improve the sensitivity in HIV—TB co-
infection, we included an early-secreted antigen, CFP-10,
apart from the 38-kDa antigen, in the present study.
Unlike 38-kDa, CFP-10 is a less reported M. tuberculosis
complex-specific RD1 antigen in serodiagnosis. The RD1
region is absent in attenuated strains of M. bovis BCG,
Mycobacterium avium, and other non-tuberculous mycobac-
teria (exceptions are Mycobacterium kansasii, Mycobacter-
ium szulgai, and Mycobacterium marinum).29—33 Since the
RD1 region is absent in M. bovis BCG, prior vaccination with
BCG will not give false-positive results.
In the present study, CFP-10 had a sensitivity of 57.4% in
HIV—TB co-infection and 57.5% in HIV-seronegative TB
patients, with a specificity of 98.1%. When the 38-kDa anti-
body response was combined with that of CFP-10, sensitivity
improved to 59.3% in HIV—TB patients and 82.9% in TB
patients. The improved sensitivity on combining the results
of both antigens may be attributed to the fact that they
recognize different sets of patients, i.e., 38-kDa reacting
with advanced cavitary cases and CFP-10 reacting with non-
cavitary cases.
Many of the earlier serodiagnostic studies in HIV—TB
considered patients as a single group, but did not classify
Figure 2 Correlation of antibody response (CFP-10) with CD4 levels of HIV infected TB patients. OD indicates optical density. Each dot
in the graph represents an individual and the straight line represents the trend of correlation between antibody response and CD4
counts of HIV—TB patients. r represents Pearson’s correlation coefficient and p represents significance of correlation.
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important group where diagnostic tests are urgently needed,
because failure to diagnose TB in this group may lead to a
higher mortality rate. In our study, 38-kDa antigen gave 28%
(7/25) sensitivity in smear-negative HIV—TB cases. The sen-
sitivity improved to 56% (14/25) when CFP-10 antigen was
also included. A similar increase to 62.1% was seen in smear-
positive cases.
Isotypes other than IgG were measured in bronchoalveolar
lavage fluid and serum in our earlier studies.16,34 Measuring
isotypes other than IgG is useful, because some samples that
were negative for IgG were still positive for IgA antibodies.
Our previous study in HIV—TB patients from South India
reported that when IgA results were added to IgG, MPT51
antigen sensitivity was augmented to 63% from 50%.26
Another study in HIV—TB patients showed improved sensitiv-
ity from 65% to 84% for 30-kDa, and from 15% to 56% for 16-
kDa antigen upon combining the isotype results.35
However, the significance of the IgA response is unclear.
Some reports state that the production of antibody of a
particular class is determined by the concentration of cyto-
kines secreted by CD4+ T-cells. Interleukin (IL)-2, IL-4, IL-6,
and interferon (IFN)-g have been found to contribute to the
formation of IgG-producing clones, while IL-3, IL-5, and
transforming growth factor (TGF)-b have been found to
contribute to the formation of IgA-producing plasma cells.36
Since our population is heterogeneous, interpreting the
cytokine profile with respect to antibody isotype is difficult,
and therefore it was not included in this study.
It is interesting to note that IgG showed 100% specificity
while IgA showed only 83.3% for CFP-10 antigen in HIV-
infected patients. The increased false-positivity in IgA is
not due to non-specificity, since in the NHS group IgA showed
98.8% specificity for this antigen. One possible reason for
such an enhanced positivity might be the ability of CFP-10 to
diagnose subjects who are progressing to active TB. Long-
term follow-up studies are needed to confirm this specula-
tion, which is beyond the scope of this paper.
In studies using different M. tuberculosis protein antigens
for HIV—TB serodiagnosis, 30-kDa has yielded a sensitivity of
0—65%35,37,38 and 27-kDa has given 50% sensitivity,26 whereas
16-kDa has shown low sensitivity.25,35 The only protein anti-gen reported in the literature to have >80% sensitivity in
HIV—TB is the malate synthase recombinant antigen
(MTB81).7 This study reported 92% sensitivity in a small
number of patients (N = 27), the majority of them from
Uganda. The same article also reported a sensitivity of 70%
for the same antigen in another cohort of 37 patients from
South Africa.
Earlier investigators have repeatedly observed that single
antigens will never suffice for highly sensitive diagnosis, even
for smear-positive cases, and that the sensitivities that could
be achieved are around 75% at best,39—41 since there is
qualitative and quantitative heterogeneity in antibody
response. This heterogeneous recognition of antigens in TB
probably arises due to multiple factors like the difference in
immunogenetic background of the infected host, stage of
their disease, bacillary load, etc. Therefore, an important
implication is that serodiagnostic assays for TB must be based
on a rational design of antigen combinations to achieve high
diagnostic accuracy. The 38-kDa protein is the antigen that
has been most studied for the serodiagnosis of TB. Because of
its species specificity, 38-kDa offers a test of>95% specificity.
But since this antigen is associated with advanced, sputum
smear-positive TB alone, sensitivity is limited to 60—70%.
Therefore the rational design for a diagnostic test is one with
multiple specific antigens, with 38-kDa definitely being one
of them. The other antigens may add to the test positivity in
cases not diagnosed by 38-kDa. It is the basis of the majority
of commercial tests for the serodiagnosis of TB.
In this way, the 38-kDa antigen has previously been com-
bined with other proteins to increase the sensitivity of the
test. A test sensitivity of 56.3%was achieved when the 38-kDa
antigen was combined with MTB48 (a gain of 12.9%).42 When
the 38-kDa antigen was mixed with MTB81, the sera from 68%
of the TB patients analyzed reacted,7 and when the 38-kDa
antigen was added to recombinant CFP-10, the rates of
antibody detection increased from 49% to 58% for smear-
positive TB patients and from 21% to 40% for smear-negative
patients.43 When 38-kDa results were combined with MPT51,
sensitivity was enhanced from 62% to 82%.26
Our control population included non-TB controls as well as
normal healthy subjects. The inclusion of this population
(which many studies do not include or include in insufficient
Diagnosis of TB in HIV-positive patients using CFP-10 621numbers) is crucial for clinical evaluation of diagnostic tests,
since they are likely to be confusedwith TB patients. Non-TB
controls might include LTBI too, since our area is endemic for
TB. Besides non-TB controls, the NHS group might also
contain LTBI. In the present study TST or the interferon-
gamma release assay (IGRA) were not done to identify latent
infection in our study population, since it is known that>70%
of females and >80% of males turn positive for PPD-S by 25
years of age due to exposure to M. tuberculosis as well as
other environmental mycobacteria.14,15 Studies have
reported 40% LTBI in healthy community controls recruited
from India.44 We observed only up to 6.3% false-positivity in
non-TB controls and 4.4% in NHS, which implies that the
serodiagnostic assay did not identify latent infection, but
only active disease.
In the present study, no significant correlation between
CD4 cell counts and antibody levels in HIV—TB patients was
observed, as demonstrated in other studies.26,45 In a study by
Ratanasuwan et al.,46 a difference in antibody response
based on the CD4 counts was observed with lipoarabinoman-
nan antigen. The sensitivity among HIV—TB patients who had
a CD4 count 200  103 cells/mm3 was significantly higher
than for patients with a CD4 count < 200  103 cells/mm3.
In the present study, routine sputum smear examination
diagnosed 29 out of 54 (53.7%) HIV—TB cases, while ELISA
identified 32/54 (59.3%). Forty-three of 54 (79.6%) HIV-posi-
tive TB cases were positive for either of the tests. Thus, it can
be concluded that ELISA, used along with sputum smear can
be a good diagnostic test for HIV—TB co-infection.
It is evident that the use of CFP-10 supplements the
sensitivity of 38-kDa antigen, and hence CFP-10 antigen
has diagnostic utility in HIV—TB as well as in HIV-negative
TB irrespective of the sputum smear status. Furthermore,
measurement of IgA antibodies along with IgG results in
better test outcomes.
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